ASH: High-dose gene transfer beneficial in severe hemophilia A

ASH: high-dose gene transfer beneficial in severe hemophilia A
(HealthDay)—For men with severe hemophilia A, high-dose factor VIII gene transfer is associated with sustained normalization of factor VIII activity levels, according to a study published online Dec. 9 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in Atlanta.

Savita Rangarajan, M.B., B.S., from Hampshire Hospitals NHS Foundation Trust in Basingstoke, U.K., and colleagues infused a single intravenous dose of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted human factor VIII (AAV5-hFVIII-SQ) in nine men with severe hemophilia A. Participants were enrolled into one of three dose cohorts (low dose [one participant], intermediate dose [one participant], and high dose [seven participants]).

The researchers found that recipients of the low or intermediate dose had factor VIII that remained at 3 IU or less/dL. In all seven participants in the high-dose cohort, the factor VIII activity level was more than 5 IU/dL between weeks two and nine after ; in six participants the level increased to a normal value (>50 IU/dL), which was maintained at one year after receipt.

"The infusion of AAV5-hFVIII-SQ was associated with the sustained normalization of factor VIII activity level over a period of one year in six of seven participants who received a ," the authors write.

The study was funded by BioMarin Pharmaceutical.


Explore further

Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A

More information: Abstract
Full Text
Editorial
More Information
Journal information: New England Journal of Medicine

Copyright © 2017 HealthDay. All rights reserved.

Citation: ASH: High-dose gene transfer beneficial in severe hemophilia A (2017, December 11) retrieved 27 May 2019 from https://medicalxpress.com/news/2017-12-ash-high-dose-gene-beneficial-severe.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more